CN101426906A - 一类新颖的以蛋白质为基础的治疗用分子 - Google Patents
一类新颖的以蛋白质为基础的治疗用分子 Download PDFInfo
- Publication number
- CN101426906A CN101426906A CNA2005800372268A CN200580037226A CN101426906A CN 101426906 A CN101426906 A CN 101426906A CN A2005800372268 A CNA2005800372268 A CN A2005800372268A CN 200580037226 A CN200580037226 A CN 200580037226A CN 101426906 A CN101426906 A CN 101426906A
- Authority
- CN
- China
- Prior art keywords
- sialidase
- nucleic acid
- territory
- acid molecule
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 125
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 88
- 230000001225 therapeutic effect Effects 0.000 title abstract description 25
- 108010006232 Neuraminidase Proteins 0.000 claims abstract description 380
- 102000005348 Neuraminidase Human genes 0.000 claims abstract description 378
- 230000000694 effects Effects 0.000 claims abstract description 159
- 241000700605 Viruses Species 0.000 claims abstract description 158
- 238000000034 method Methods 0.000 claims abstract description 119
- 239000000203 mixture Substances 0.000 claims abstract description 103
- 230000001717 pathogenic effect Effects 0.000 claims abstract description 84
- 230000002708 enhancing effect Effects 0.000 claims abstract description 8
- 208000010668 atopic eczema Diseases 0.000 claims abstract description 5
- 238000011282 treatment Methods 0.000 claims description 166
- 230000004927 fusion Effects 0.000 claims description 130
- 230000003197 catalytic effect Effects 0.000 claims description 127
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 93
- 239000003814 drug Substances 0.000 claims description 86
- 241000186044 Actinomyces viscosus Species 0.000 claims description 76
- 108020004707 nucleic acids Proteins 0.000 claims description 76
- 150000007523 nucleic acids Chemical class 0.000 claims description 76
- 102000039446 nucleic acids Human genes 0.000 claims description 76
- 150000001413 amino acids Chemical class 0.000 claims description 75
- 239000003795 chemical substances by application Substances 0.000 claims description 63
- 206010022000 influenza Diseases 0.000 claims description 54
- 230000002265 prevention Effects 0.000 claims description 38
- 125000003729 nucleotide group Chemical group 0.000 claims description 37
- 239000002773 nucleotide Substances 0.000 claims description 31
- 239000013604 expression vector Substances 0.000 claims description 30
- 230000027455 binding Effects 0.000 claims description 29
- 210000002919 epithelial cell Anatomy 0.000 claims description 28
- 239000002253 acid Substances 0.000 claims description 24
- 230000009385 viral infection Effects 0.000 claims description 21
- 239000013603 viral vector Substances 0.000 claims description 20
- 239000007922 nasal spray Substances 0.000 claims description 19
- 229940097496 nasal spray Drugs 0.000 claims description 19
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 18
- 102000007299 Amphiregulin Human genes 0.000 claims description 17
- 108010033760 Amphiregulin Proteins 0.000 claims description 17
- 239000000243 solution Substances 0.000 claims description 15
- 239000013598 vector Substances 0.000 claims description 13
- 239000000725 suspension Substances 0.000 claims description 12
- 241000606768 Haemophilus influenzae Species 0.000 claims description 11
- 241000193998 Streptococcus pneumoniae Species 0.000 claims description 11
- 230000008521 reorganization Effects 0.000 claims description 11
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims description 11
- 102000004411 Antithrombin III Human genes 0.000 claims description 10
- 108090000935 Antithrombin III Proteins 0.000 claims description 10
- 241000186063 Arthrobacter Species 0.000 claims description 10
- 229960005348 antithrombin iii Drugs 0.000 claims description 10
- 239000004202 carbamide Substances 0.000 claims description 10
- 239000007921 spray Substances 0.000 claims description 10
- 208000002606 Paramyxoviridae Infections Diseases 0.000 claims description 9
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 9
- 206010061218 Inflammation Diseases 0.000 claims description 8
- 125000000539 amino acid group Chemical group 0.000 claims description 8
- 230000004054 inflammatory process Effects 0.000 claims description 8
- 238000002347 injection Methods 0.000 claims description 8
- 239000007924 injection Substances 0.000 claims description 8
- 239000002674 ointment Substances 0.000 claims description 8
- 241000187708 Micromonospora Species 0.000 claims description 7
- 102000012605 Cystic Fibrosis Transmembrane Conductance Regulator Human genes 0.000 claims description 6
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 claims description 6
- 241000590002 Helicobacter pylori Species 0.000 claims description 6
- 241000202934 Mycoplasma pneumoniae Species 0.000 claims description 6
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 6
- 201000010105 allergic rhinitis Diseases 0.000 claims description 6
- 208000006673 asthma Diseases 0.000 claims description 6
- 239000003889 eye drop Substances 0.000 claims description 6
- 229940037467 helicobacter pylori Drugs 0.000 claims description 6
- 230000005012 migration Effects 0.000 claims description 6
- 238000013508 migration Methods 0.000 claims description 6
- 230000002792 vascular Effects 0.000 claims description 6
- 101000771674 Homo sapiens Apolipoprotein E Proteins 0.000 claims description 5
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 claims description 5
- ILRKKHJEINIICQ-OOFFSTKBSA-N Monoammonium glycyrrhizinate Chemical compound N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ILRKKHJEINIICQ-OOFFSTKBSA-N 0.000 claims description 5
- 241000725643 Respiratory syncytial virus Species 0.000 claims description 5
- 108010090804 Streptavidin Proteins 0.000 claims description 5
- 239000001685 glycyrrhizic acid Substances 0.000 claims description 5
- 102000053020 human ApoE Human genes 0.000 claims description 5
- 102000052624 human CXCL8 Human genes 0.000 claims description 5
- 101150084651 Neu2 gene Proteins 0.000 claims description 4
- 210000001772 blood platelet Anatomy 0.000 claims description 4
- 239000000499 gel Substances 0.000 claims description 4
- 230000000699 topical effect Effects 0.000 claims description 4
- 241000701161 unidentified adenovirus Species 0.000 claims description 4
- 101000583741 Clostridium perfringens Sialidase Proteins 0.000 claims description 3
- 201000004624 Dermatitis Diseases 0.000 claims description 3
- 231100000742 Plant toxin Toxicity 0.000 claims description 3
- 239000007937 lozenge Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 231100000611 venom Toxicity 0.000 claims description 3
- 229920002101 Chitin Polymers 0.000 claims description 2
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 claims description 2
- 230000005784 autoimmunity Effects 0.000 claims description 2
- 244000052616 bacterial pathogen Species 0.000 claims description 2
- 230000010856 establishment of protein localization Effects 0.000 claims description 2
- 230000012846 protein folding Effects 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 19
- 238000001742 protein purification Methods 0.000 claims 3
- 210000004907 gland Anatomy 0.000 claims 2
- 102000000584 Calmodulin Human genes 0.000 claims 1
- 108010041952 Calmodulin Proteins 0.000 claims 1
- 230000017730 intein-mediated protein splicing Effects 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 230000032696 parturition Effects 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 230000029983 protein stabilization Effects 0.000 claims 1
- 230000001177 retroviral effect Effects 0.000 claims 1
- 241001529453 unidentified herpesvirus Species 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 151
- 208000015181 infectious disease Diseases 0.000 abstract description 102
- 230000026683 transduction Effects 0.000 abstract description 27
- 238000010361 transduction Methods 0.000 abstract description 27
- 244000052769 pathogen Species 0.000 abstract description 19
- 230000028709 inflammatory response Effects 0.000 abstract description 18
- 238000001415 gene therapy Methods 0.000 abstract description 13
- 230000000172 allergic effect Effects 0.000 abstract description 2
- 238000004873 anchoring Methods 0.000 abstract 1
- 108020001778 catalytic domains Proteins 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 310
- 108010039627 Aprotinin Proteins 0.000 description 79
- 235000018102 proteins Nutrition 0.000 description 79
- 239000002753 trypsin inhibitor Substances 0.000 description 77
- 229940122618 Trypsin inhibitor Drugs 0.000 description 76
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 76
- 101710162629 Trypsin inhibitor Proteins 0.000 description 72
- 229940108519 trasylol Drugs 0.000 description 72
- 229940024606 amino acid Drugs 0.000 description 65
- 235000001014 amino acid Nutrition 0.000 description 65
- 241000894006 Bacteria Species 0.000 description 64
- 241000712461 unidentified influenza virus Species 0.000 description 63
- 125000003275 alpha amino acid group Chemical group 0.000 description 50
- 108090000790 Enzymes Proteins 0.000 description 48
- 102000004190 Enzymes Human genes 0.000 description 47
- 229940088598 enzyme Drugs 0.000 description 46
- 101710154606 Hemagglutinin Proteins 0.000 description 44
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 44
- 241001465754 Metazoa Species 0.000 description 43
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 42
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 42
- 101710176177 Protein A56 Proteins 0.000 description 42
- 229940079593 drug Drugs 0.000 description 42
- 239000000185 hemagglutinin Substances 0.000 description 42
- 102000004196 processed proteins & peptides Human genes 0.000 description 33
- 229920002683 Glycosaminoglycan Polymers 0.000 description 29
- 102000035195 Peptidases Human genes 0.000 description 25
- 108091005804 Peptidases Proteins 0.000 description 25
- 229920001184 polypeptide Polymers 0.000 description 24
- 238000012545 processing Methods 0.000 description 24
- 230000014509 gene expression Effects 0.000 description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 20
- 239000002953 phosphate buffered saline Substances 0.000 description 20
- 238000012360 testing method Methods 0.000 description 20
- 238000013016 damping Methods 0.000 description 18
- 210000000981 epithelium Anatomy 0.000 description 18
- 239000012530 fluid Substances 0.000 description 18
- 210000001331 nose Anatomy 0.000 description 18
- 210000002345 respiratory system Anatomy 0.000 description 18
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 17
- 241000282341 Mustela putorius furo Species 0.000 description 17
- 238000004458 analytical method Methods 0.000 description 17
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 17
- 239000000126 substance Substances 0.000 description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 16
- 230000006870 function Effects 0.000 description 16
- 229920000669 heparin Polymers 0.000 description 16
- 229960002897 heparin Drugs 0.000 description 16
- 108020003175 receptors Proteins 0.000 description 16
- 102000005962 receptors Human genes 0.000 description 16
- 230000008859 change Effects 0.000 description 15
- 238000011534 incubation Methods 0.000 description 15
- 230000000840 anti-viral effect Effects 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 14
- 239000000758 substrate Substances 0.000 description 14
- 230000003612 virological effect Effects 0.000 description 14
- 108020004414 DNA Proteins 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 13
- 230000001580 bacterial effect Effects 0.000 description 13
- 201000010099 disease Diseases 0.000 description 13
- 230000005764 inhibitory process Effects 0.000 description 13
- 239000002609 medium Substances 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 238000012546 transfer Methods 0.000 description 13
- 241001500351 Influenzavirus A Species 0.000 description 12
- 238000003776 cleavage reaction Methods 0.000 description 12
- 210000004969 inflammatory cell Anatomy 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 230000007017 scission Effects 0.000 description 12
- 241000193468 Clostridium perfringens Species 0.000 description 11
- 101000601384 Homo sapiens Sialidase-4 Proteins 0.000 description 11
- 102100037729 Sialidase-4 Human genes 0.000 description 11
- 230000000968 intestinal effect Effects 0.000 description 11
- 239000010410 layer Substances 0.000 description 11
- 239000008194 pharmaceutical composition Substances 0.000 description 11
- 230000008569 process Effects 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 239000004365 Protease Substances 0.000 description 10
- 230000037396 body weight Effects 0.000 description 10
- 150000001720 carbohydrates Chemical class 0.000 description 10
- 102000037865 fusion proteins Human genes 0.000 description 10
- 108020001507 fusion proteins Proteins 0.000 description 10
- 230000001976 improved effect Effects 0.000 description 10
- 150000002632 lipids Chemical class 0.000 description 10
- 210000001533 respiratory mucosa Anatomy 0.000 description 10
- 230000002269 spontaneous effect Effects 0.000 description 10
- 108020004705 Codon Proteins 0.000 description 9
- 101001123851 Homo sapiens Sialidase-2 Proteins 0.000 description 9
- 206010020751 Hypersensitivity Diseases 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 208000026935 allergic disease Diseases 0.000 description 9
- 230000007815 allergy Effects 0.000 description 9
- -1 amide compound Chemical class 0.000 description 9
- 235000014633 carbohydrates Nutrition 0.000 description 9
- 238000001514 detection method Methods 0.000 description 9
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 125000005629 sialic acid group Chemical group 0.000 description 9
- 241000894007 species Species 0.000 description 9
- 239000003053 toxin Substances 0.000 description 9
- 231100000765 toxin Toxicity 0.000 description 9
- 241000271566 Aves Species 0.000 description 8
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 8
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 8
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 8
- 210000000170 cell membrane Anatomy 0.000 description 8
- 238000005520 cutting process Methods 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- 210000004072 lung Anatomy 0.000 description 8
- 235000019419 proteases Nutrition 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 241000287828 Gallus gallus Species 0.000 description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 7
- 102000004890 Interleukin-8 Human genes 0.000 description 7
- 108090001007 Interleukin-8 Proteins 0.000 description 7
- 206010057190 Respiratory tract infections Diseases 0.000 description 7
- 241000282898 Sus scrofa Species 0.000 description 7
- 230000009089 cytolysis Effects 0.000 description 7
- 230000000120 cytopathologic effect Effects 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 239000002243 precursor Substances 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 230000000241 respiratory effect Effects 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- 101710095339 Apolipoprotein E Proteins 0.000 description 6
- 102100029470 Apolipoprotein E Human genes 0.000 description 6
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 6
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 6
- 102000003886 Glycoproteins Human genes 0.000 description 6
- 108090000288 Glycoproteins Proteins 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- 108091093037 Peptide nucleic acid Proteins 0.000 description 6
- 102100028755 Sialidase-2 Human genes 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 150000005829 chemical entities Chemical class 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 210000002744 extracellular matrix Anatomy 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 210000000214 mouth Anatomy 0.000 description 6
- 229920001542 oligosaccharide Polymers 0.000 description 6
- 150000002482 oligosaccharides Chemical class 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 150000003431 steroids Chemical class 0.000 description 6
- 230000009466 transformation Effects 0.000 description 6
- 229960005486 vaccine Drugs 0.000 description 6
- 201000004813 Bronchopneumonia Diseases 0.000 description 5
- 241000711573 Coronaviridae Species 0.000 description 5
- 241000283073 Equus caballus Species 0.000 description 5
- 241000712431 Influenza A virus Species 0.000 description 5
- 241000282339 Mustela Species 0.000 description 5
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 102000013566 Plasminogen Human genes 0.000 description 5
- 108010051456 Plasminogen Proteins 0.000 description 5
- 206010035664 Pneumonia Diseases 0.000 description 5
- 229920002684 Sepharose Polymers 0.000 description 5
- 102000012479 Serine Proteases Human genes 0.000 description 5
- 108010022999 Serine Proteases Proteins 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 125000001931 aliphatic group Chemical group 0.000 description 5
- 229960004405 aprotinin Drugs 0.000 description 5
- 230000005540 biological transmission Effects 0.000 description 5
- 230000001120 cytoprotective effect Effects 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 210000003630 histaminocyte Anatomy 0.000 description 5
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 229930182817 methionine Natural products 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 210000003928 nasal cavity Anatomy 0.000 description 5
- 238000005457 optimization Methods 0.000 description 5
- 230000000644 propagated effect Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 238000013519 translation Methods 0.000 description 5
- 239000005723 virus inoculator Substances 0.000 description 5
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 4
- 102100040356 Angio-associated migratory cell protein Human genes 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 229930186217 Glycolipid Natural products 0.000 description 4
- 241000606790 Haemophilus Species 0.000 description 4
- 229920002971 Heparan sulfate Polymers 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 101000964180 Homo sapiens Angio-associated migratory cell protein Proteins 0.000 description 4
- 241001500350 Influenzavirus B Species 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 108091092195 Intron Proteins 0.000 description 4
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 4
- 241000702670 Rotavirus Species 0.000 description 4
- 108010047827 Sialic Acid Binding Immunoglobulin-like Lectins Proteins 0.000 description 4
- 102000007073 Sialic Acid Binding Immunoglobulin-like Lectins Human genes 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 229910002091 carbon monoxide Inorganic materials 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 230000000857 drug effect Effects 0.000 description 4
- 238000004043 dyeing Methods 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 210000003725 endotheliocyte Anatomy 0.000 description 4
- 210000002615 epidermis Anatomy 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 4
- 210000005260 human cell Anatomy 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 208000037797 influenza A Diseases 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 4
- 229940096397 interleukin-8 Drugs 0.000 description 4
- 210000003563 lymphoid tissue Anatomy 0.000 description 4
- 238000005375 photometry Methods 0.000 description 4
- 231100000614 poison Toxicity 0.000 description 4
- 239000002574 poison Substances 0.000 description 4
- 238000011321 prophylaxis Methods 0.000 description 4
- 235000019833 protease Nutrition 0.000 description 4
- 108020001580 protein domains Proteins 0.000 description 4
- 238000010010 raising Methods 0.000 description 4
- 230000009257 reactivity Effects 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 108010088751 Albumins Proteins 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 3
- 206010002198 Anaphylactic reaction Diseases 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 241000282465 Canis Species 0.000 description 3
- 241000702421 Dependoparvovirus Species 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 101000863884 Homo sapiens Sialic acid-binding Ig-like lectin 8 Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 241000187750 Micromonospora viridifaciens Species 0.000 description 3
- 241000589516 Pseudomonas Species 0.000 description 3
- 206010039101 Rhinorrhoea Diseases 0.000 description 3
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 3
- 102100029964 Sialic acid-binding Ig-like lectin 8 Human genes 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 241000405217 Viola <butterfly> Species 0.000 description 3
- 230000036783 anaphylactic response Effects 0.000 description 3
- 208000003455 anaphylaxis Diseases 0.000 description 3
- 230000002924 anti-infective effect Effects 0.000 description 3
- 239000004599 antimicrobial Substances 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- HSHNITRMYYLLCV-UHFFFAOYSA-N beta-methyl umbelliferone Natural products C1=C(O)C=CC2=C1OC(=O)C=C2C HSHNITRMYYLLCV-UHFFFAOYSA-N 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 210000000621 bronchi Anatomy 0.000 description 3
- 210000000424 bronchial epithelial cell Anatomy 0.000 description 3
- 230000003139 buffering effect Effects 0.000 description 3
- 239000013553 cell monolayer Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 230000008034 disappearance Effects 0.000 description 3
- 239000006196 drop Substances 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 150000002270 gangliosides Chemical class 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 229940025294 hemin Drugs 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 229960003971 influenza vaccine Drugs 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 229910021645 metal ion Inorganic materials 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 208000010753 nasal discharge Diseases 0.000 description 3
- 230000004768 organ dysfunction Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 210000003800 pharynx Anatomy 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 230000003014 reinforcing effect Effects 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- 229960000888 rimantadine Drugs 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 238000005199 ultracentrifugation Methods 0.000 description 3
- 230000029812 viral genome replication Effects 0.000 description 3
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 3
- 235000001892 vitamin D2 Nutrition 0.000 description 3
- 239000011653 vitamin D2 Substances 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 description 2
- DIOSHTLNZVXJOF-UHFFFAOYSA-N 2,5-bis(3-oxobutanoylamino)benzenesulfonic acid Chemical compound CC(=O)CC(=O)NC1=CC=C(NC(=O)CC(C)=O)C(S(O)(=O)=O)=C1 DIOSHTLNZVXJOF-UHFFFAOYSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 2
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 241000606161 Chlamydia Species 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 201000003883 Cystic fibrosis Diseases 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 108090000144 Human Proteins Proteins 0.000 description 2
- 102000003839 Human Proteins Human genes 0.000 description 2
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 241000713196 Influenza B virus Species 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 108090000862 Ion Channels Proteins 0.000 description 2
- 102000004310 Ion Channels Human genes 0.000 description 2
- 206010022998 Irritability Diseases 0.000 description 2
- 102000001399 Kallikrein Human genes 0.000 description 2
- 108060005987 Kallikrein Proteins 0.000 description 2
- 125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 108090000856 Lyases Proteins 0.000 description 2
- 102000004317 Lyases Human genes 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 241000712464 Orthomyxoviridae Species 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 241001524178 Paenarthrobacter ureafaciens Species 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 108010067787 Proteoglycans Proteins 0.000 description 2
- 102000016611 Proteoglycans Human genes 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- 108010073771 Soybean Proteins Proteins 0.000 description 2
- 240000007591 Tilia tomentosa Species 0.000 description 2
- 241000607626 Vibrio cholerae Species 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- KLOHDWPABZXLGI-YWUHCJSESA-M ampicillin sodium Chemical compound [Na+].C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C([O-])=O)(C)C)=CC=CC=C1 KLOHDWPABZXLGI-YWUHCJSESA-M 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- 229960004217 benzyl alcohol Drugs 0.000 description 2
- 230000003570 biosynthesizing effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000001311 chemical methods and process Methods 0.000 description 2
- 210000004081 cilia Anatomy 0.000 description 2
- 238000005352 clarification Methods 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000009849 deactivation Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000000593 degrading effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 239000002532 enzyme inhibitor Substances 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000008098 formaldehyde solution Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000035931 haemagglutination Effects 0.000 description 2
- 230000012447 hatching Effects 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 208000037798 influenza B Diseases 0.000 description 2
- 229940102223 injectable solution Drugs 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000011229 interlayer Substances 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 201000009240 nasopharyngitis Diseases 0.000 description 2
- 210000001989 nasopharynx Anatomy 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000007026 protein scission Effects 0.000 description 2
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 238000003345 scintillation counting Methods 0.000 description 2
- 210000002955 secretory cell Anatomy 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 238000010008 shearing Methods 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 230000016160 smooth muscle contraction Effects 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 235000019710 soybean protein Nutrition 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 238000012384 transportation and delivery Methods 0.000 description 2
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 2
- 229940038773 trisodium citrate Drugs 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 229940118696 vibrio cholerae Drugs 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- MEIRRNXMZYDVDW-MQQKCMAXSA-N (2E,4E)-2,4-hexadien-1-ol Chemical compound C\C=C\C=C\CO MEIRRNXMZYDVDW-MQQKCMAXSA-N 0.000 description 1
- NTQVODZUQIATFS-WAUHAFJUSA-N (2s)-2-[[(2s)-6-amino-2-[[2-[[(2s,3s)-2-[[(2s)-2-[[(2s)-2-amino-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-methylpentanoyl]amino]acetyl]amino]hexanoyl]amino]-3-methylbutanoic acid Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O NTQVODZUQIATFS-WAUHAFJUSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- GGRLKHMFMUXIOG-UHFFFAOYSA-M 2-acetyloxyethyl(trimethyl)azanium;hydroxide Chemical compound [OH-].CC(=O)OCC[N+](C)(C)C GGRLKHMFMUXIOG-UHFFFAOYSA-M 0.000 description 1
- FHYNZKLNCPUNEU-UHFFFAOYSA-N 4-[(3,4-dihydroxyphenyl)methyl]-3-[(4-hydroxyphenyl)methyl]oxolan-2-one Chemical compound C1=CC(O)=CC=C1CC1C(=O)OCC1CC1=CC=C(O)C(O)=C1 FHYNZKLNCPUNEU-UHFFFAOYSA-N 0.000 description 1
- WGTSSIAUHVVZGA-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-N,N-dimethylaniline dihydrochloride Chemical compound Cl.Cl.CN(C1=CC=C(C2=CC=C(N(C)C)C=C2)C=C1)C WGTSSIAUHVVZGA-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 102100026041 Acrosin Human genes 0.000 description 1
- 108090000107 Acrosin Proteins 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 206010001076 Acute sinusitis Diseases 0.000 description 1
- 241000321096 Adenoides Species 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 101710186708 Agglutinin Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 108010002913 Asialoglycoproteins Proteins 0.000 description 1
- 241000711404 Avian avulavirus 1 Species 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101000984722 Bos taurus Pancreatic trypsin inhibitor Proteins 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 239000012619 Butyl Sepharose® Substances 0.000 description 1
- 101150029409 CFTR gene Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 102000012286 Chitinases Human genes 0.000 description 1
- 108010022172 Chitinases Proteins 0.000 description 1
- 241000724565 Chorella virus Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 101100136092 Drosophila melanogaster peng gene Proteins 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 206010063045 Effusion Diseases 0.000 description 1
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 101000925662 Enterobacteria phage PRD1 Endolysin Proteins 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 241001076388 Fimbria Species 0.000 description 1
- 241000712469 Fowl plague virus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 108010063907 Glutathione Reductase Proteins 0.000 description 1
- 102100036442 Glutathione reductase, mitochondrial Human genes 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000589989 Helicobacter Species 0.000 description 1
- 206010019375 Helicobacter infections Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 1
- 101001123847 Homo sapiens Sialidase-3 Proteins 0.000 description 1
- 101710146024 Horcolin Proteins 0.000 description 1
- 208000012860 Horse disease Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 241001500343 Influenzavirus C Species 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 125000000570 L-alpha-aspartyl group Chemical group [H]OC(=O)C([H])([H])[C@]([H])(N([H])[H])C(*)=O 0.000 description 1
- 125000002061 L-isoleucyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](C([H])([H])[H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000003440 L-leucyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(C([H])([H])[H])([H])C([H])([H])[H] 0.000 description 1
- 125000002435 L-phenylalanyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000003798 L-tyrosyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 description 1
- 101710189395 Lectin Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 101710179758 Mannose-specific lectin Proteins 0.000 description 1
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 description 1
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 102000015728 Mucins Human genes 0.000 description 1
- 108010063954 Mucins Proteins 0.000 description 1
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 1
- 241000158526 Nasalis Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 230000010748 Photoabsorption Effects 0.000 description 1
- 108090000113 Plasma Kallikrein Proteins 0.000 description 1
- 102100034869 Plasma kallikrein Human genes 0.000 description 1
- 102000004211 Platelet factor 4 Human genes 0.000 description 1
- 108090000778 Platelet factor 4 Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000206607 Porphyra umbilicalis Species 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 101710121440 Proteinase-activated receptor 1 Proteins 0.000 description 1
- 102100037132 Proteinase-activated receptor 2 Human genes 0.000 description 1
- 101710121435 Proteinase-activated receptor 2 Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 208000018569 Respiratory Tract disease Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000125258 Scandix pecten-veneris Species 0.000 description 1
- CWHJIJJSDGEHNS-MYLFLSLOSA-N Senegenin Chemical compound C1[C@H](O)[C@H](O)[C@@](C)(C(O)=O)[C@@H]2CC[C@@]3(C)C(CC[C@]4(CCC(C[C@H]44)(C)C)C(O)=O)=C4[C@@H](CCl)C[C@@H]3[C@]21C CWHJIJJSDGEHNS-MYLFLSLOSA-N 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 102000008847 Serpin Human genes 0.000 description 1
- 108050000761 Serpin Proteins 0.000 description 1
- 108010029176 Sialic Acid Binding Ig-like Lectin 1 Proteins 0.000 description 1
- 108010029157 Sialic Acid Binding Ig-like Lectin 2 Proteins 0.000 description 1
- 241000501499 Sialis Species 0.000 description 1
- 102100032855 Sialoadhesin Human genes 0.000 description 1
- 108010032838 Sialoglycoproteins Proteins 0.000 description 1
- 102000007365 Sialoglycoproteins Human genes 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 101001039853 Sonchus yellow net virus Matrix protein Proteins 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 102000018265 Virus Receptors Human genes 0.000 description 1
- 108010066342 Virus Receptors Proteins 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000002534 adenoid Anatomy 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 239000000910 agglutinin Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 210000001552 airway epithelial cell Anatomy 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 238000011951 anti-virus test Methods 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000011203 antimicrobial therapy Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000003289 ascorbyl group Chemical class [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- CFTILMCYFKFDKM-UHFFFAOYSA-N azane;propane-1,2,3-triol Chemical compound N.OCC(O)CO CFTILMCYFKFDKM-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000010065 bacterial adhesion Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 210000003912 basophilic leucocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 208000011090 bird disease Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 230000007885 bronchoconstriction Effects 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000017455 cell-cell adhesion Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 210000003837 chick embryo Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940038704 clostridium perfringens Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 239000004064 cosurfactant Substances 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000010460 detection of virus Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000013024 dilution buffer Substances 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 208000019258 ear infection Diseases 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 210000000222 eosinocyte Anatomy 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000002836 epithelial cell of stomach Anatomy 0.000 description 1
- QTTMOCOWZLSYSV-QWAPEVOJSA-M equilin sodium sulfate Chemical compound [Na+].[O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1 QTTMOCOWZLSYSV-QWAPEVOJSA-M 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- OBNCKNCVKJNDBV-UHFFFAOYSA-N ethyl butyrate Chemical compound CCCC(=O)OCC OBNCKNCVKJNDBV-UHFFFAOYSA-N 0.000 description 1
- FKRCODPIKNYEAC-UHFFFAOYSA-N ethyl propionate Chemical compound CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 238000001424 field-emission electron microscopy Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- 238000005558 fluorometry Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 150000002339 glycosphingolipids Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000003677 hemocyte Anatomy 0.000 description 1
- 229940000351 hemocyte Drugs 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 230000007236 host immunity Effects 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000022760 infectious otitis media Diseases 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 208000037799 influenza C Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000013178 mathematical model Methods 0.000 description 1
- 239000011159 matrix material Chemical group 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- DEOKFPFLXFNAON-NTISSMGPSA-N n-[(2s)-5-(diaminomethylideneamino)-1-(4-nitroanilino)-1-oxopentan-2-yl]benzamide;hydrochloride Chemical compound Cl.N([C@@H](CCCN=C(N)N)C(=O)NC=1C=CC(=CC=1)[N+]([O-])=O)C(=O)C1=CC=CC=C1 DEOKFPFLXFNAON-NTISSMGPSA-N 0.000 description 1
- UPSFMJHZUCSEHU-JYGUBCOQSA-N n-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4r,5r,6s)-5-acetamido-4-hydroxy-2-(hydroxymethyl)-6-(4-methyl-2-oxochromen-7-yl)oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](NC(C)=O)[C@H](OC=2C=C3OC(=O)C=C(C)C3=CC=2)O[C@@H]1CO UPSFMJHZUCSEHU-JYGUBCOQSA-N 0.000 description 1
- YFCUZWYIPBUQBD-ZOWNYOTGSA-N n-[(3s)-7-amino-1-chloro-2-oxoheptan-3-yl]-4-methylbenzenesulfonamide;hydron;chloride Chemical compound Cl.CC1=CC=C(S(=O)(=O)N[C@@H](CCCCN)C(=O)CCl)C=C1 YFCUZWYIPBUQBD-ZOWNYOTGSA-N 0.000 description 1
- VBEGHXKAFSLLGE-UHFFFAOYSA-N n-phenylnitramide Chemical compound [O-][N+](=O)NC1=CC=CC=C1 VBEGHXKAFSLLGE-UHFFFAOYSA-N 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 239000006225 natural substrate Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229940100691 oral capsule Drugs 0.000 description 1
- 229940100629 oral lozenge Drugs 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 210000002220 organoid Anatomy 0.000 description 1
- 210000003300 oropharynx Anatomy 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- PGZUMBJQJWIWGJ-ONAKXNSWSA-N oseltamivir phosphate Chemical compound OP(O)(O)=O.CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 PGZUMBJQJWIWGJ-ONAKXNSWSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N p-menthan-3-ol Chemical compound CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 210000004043 pneumocyte Anatomy 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 238000000247 postprecipitation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000003001 serine protease inhibitor Substances 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 125000005630 sialyl group Chemical group 0.000 description 1
- 238000011125 single therapy Methods 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 229960004249 sodium acetate Drugs 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007655 standard test method Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000005127 stratified epithelium Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229940061367 tamiflu Drugs 0.000 description 1
- 239000009871 tenuigenin Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 210000005062 tracheal ring Anatomy 0.000 description 1
- 238000005829 trimerization reaction Methods 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 108010036927 trypsin-like serine protease Proteins 0.000 description 1
- 108010015530 tryptase Clara Proteins 0.000 description 1
- 239000006150 trypticase soy agar Substances 0.000 description 1
- 108010050327 trypticase-soy broth Proteins 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 description 1
- 229960001028 zanamivir Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N15/75—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Bacillus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Plant Pathology (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
蛋白质 | KdnM(ref) |
PF4 | 27(44) |
IL-8 | <5(43) |
ATIII | 11(42) |
ApoE | 62(45) |
Claims (129)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310239638.6A CN104017787B (zh) | 2004-09-10 | 2005-07-21 | 一类新颖的以蛋白质为基础的治疗用分子 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/939,262 US7807174B2 (en) | 2002-11-22 | 2004-09-10 | Class of therapeutic protein based molecules |
US10/939,262 | 2004-09-10 | ||
PCT/US2005/025831 WO2006031291A2 (en) | 2004-09-10 | 2005-07-21 | A novel class of therapeutic protein based molecules |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310239638.6A Division CN104017787B (zh) | 2004-09-10 | 2005-07-21 | 一类新颖的以蛋白质为基础的治疗用分子 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101426906A true CN101426906A (zh) | 2009-05-06 |
CN101426906B CN101426906B (zh) | 2013-06-26 |
Family
ID=36060467
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2005800372268A Active CN101426906B (zh) | 2004-09-10 | 2005-07-21 | 一类新颖的以蛋白质为基础的治疗用分子 |
CN201310239638.6A Active CN104017787B (zh) | 2004-09-10 | 2005-07-21 | 一类新颖的以蛋白质为基础的治疗用分子 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310239638.6A Active CN104017787B (zh) | 2004-09-10 | 2005-07-21 | 一类新颖的以蛋白质为基础的治疗用分子 |
Country Status (17)
Country | Link |
---|---|
US (2) | US7807174B2 (zh) |
EP (4) | EP3530734A1 (zh) |
JP (2) | JP4764881B2 (zh) |
KR (1) | KR20070064619A (zh) |
CN (2) | CN101426906B (zh) |
AU (1) | AU2005285461B2 (zh) |
BR (1) | BRPI0515646B8 (zh) |
CA (2) | CA2823429C (zh) |
DK (3) | DK3018204T3 (zh) |
ES (3) | ES2554787T3 (zh) |
HK (2) | HK1201562A1 (zh) |
IL (3) | IL181779A (zh) |
PT (3) | PT3018204T (zh) |
RU (1) | RU2468080C2 (zh) |
TR (1) | TR201905393T4 (zh) |
WO (1) | WO2006031291A2 (zh) |
ZA (1) | ZA200702915B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111065733A (zh) * | 2017-09-05 | 2020-04-24 | 角斗士生物科学公司 | 靶向外泌体的方法 |
CN111183220A (zh) * | 2017-05-26 | 2020-05-19 | 杰诺维斯公司 | 用于聚糖分析的工具 |
CN111450236A (zh) * | 2020-02-25 | 2020-07-28 | 西北大学 | 一种用于阻断冠状病毒感染的制剂 |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100210528A1 (en) * | 1999-03-05 | 2010-08-19 | Leland Shapiro | Compositions, methods and uses for inhibition and/or treatment of influenza infection |
US7807174B2 (en) * | 2002-11-22 | 2010-10-05 | Nexbio, Inc. | Class of therapeutic protein based molecules |
WO2004047735A2 (en) * | 2002-11-22 | 2004-06-10 | Mang Yu | Broad spectrum anti-viral therapeutics and prophylaxis |
US8512710B2 (en) | 2002-11-22 | 2013-08-20 | Ansun Biopharma, Inc. | Class of therapeutic protein based molecules |
KR100910092B1 (ko) * | 2004-11-10 | 2009-07-30 | 히다치 가세고교 가부시끼가이샤 | 접착 보조제 부착 금속박 및 이를 이용한 인쇄 배선판 |
CA2627323A1 (en) * | 2005-10-25 | 2007-05-03 | Mnd Diagnostic Ltd. | Compositions for- detecting of influenza viruses and kits and methods using same |
AU2013237761B8 (en) * | 2006-01-24 | 2015-06-04 | Ansun Biopharma, Inc. | Technology for preparation of macromolecular microspheres |
EP1981483A1 (en) * | 2006-01-24 | 2008-10-22 | Nexbio, Inc. | Technology for preparation of macromolecular microspheres |
AU2015215955B2 (en) * | 2006-01-24 | 2016-12-01 | Ansun Biopharma, Inc. | Technology for preparation of macromolecular microspheres |
US8273381B1 (en) * | 2006-04-14 | 2012-09-25 | Auburn University | Compositions for and methods of controlling olfactory responses to odorants |
WO2008076938A1 (en) * | 2006-12-14 | 2008-06-26 | University Of Iowa Research Foundation | Method of making cyclic polypeptides with inteins |
ES2492469T3 (es) * | 2007-02-20 | 2014-09-09 | Dsm Ip Assets B.V. | Nueva sialidasa |
JP5676258B2 (ja) | 2007-08-03 | 2015-02-25 | ロマーク ラボラトリース,エル.シー. | アルキルスルホニル置換チアゾリド化合物 |
JP5918124B2 (ja) | 2009-05-12 | 2016-05-18 | ロマーク ラボラトリーズ エル.シー. | ハロアルキルヘテロアリールベンズアミド化合物 |
MX341877B (es) | 2009-06-26 | 2016-09-06 | Romark Laboratories L C * | Compuestos y métodos para tratar influenza. |
BR112012002163A2 (pt) * | 2009-07-31 | 2015-11-03 | Danisco Us Inc | proteases com regiões pré-pró modificadas |
JP2013510169A (ja) * | 2009-11-06 | 2013-03-21 | ネクスバイオ,インク. | 呼吸器管の治療及び予防のための方法、化合物、及び組成物 |
CA2864746A1 (en) * | 2012-02-17 | 2013-08-22 | Ansun Biopharma, Inc. | Methods, compounds and compositions for treatment of influenza and parainfluenza patients |
EP2877204A2 (en) * | 2012-06-28 | 2015-06-03 | Ansun Biopharma, Inc. | Microparticle formulations for delivery to the upper and central respiratory tract and methods of manufacture |
EP2866792A4 (en) | 2012-06-28 | 2016-08-17 | Ansun Biopharma Inc | MICROPARTICLE FORMULATIONS FOR DELIVERY TO LOWER AND CENTRAL RESPIRATORY PATHS AND METHOD OF PREPARING THEM |
EP3572090B1 (en) | 2012-12-24 | 2022-12-14 | Coagulant Therapeutics Corporation | Short-acting factor vii polypeptides |
KR102186997B1 (ko) | 2013-03-15 | 2020-12-07 | 안선 바이오파르마, 아이엔씨. | 단백질 정제의 신규한 방법 |
WO2014197485A1 (en) * | 2013-06-03 | 2014-12-11 | Ansun Biopharma, Inc. | Anti-viral therapeutic for infection of the eye |
US10300116B2 (en) | 2013-06-10 | 2019-05-28 | Ansun Biopharma, Inc. | Treatment for BK polyomavirus infection |
US20160120961A1 (en) * | 2013-06-10 | 2016-05-05 | Ansun Biopharma, Inc. | Treatment of merkel cell polyomavirus infection |
US20170119859A1 (en) | 2014-05-30 | 2017-05-04 | Ansun Biopharma, Inc. | Treatment of middle east respiratory syndrome coronavirus |
US10328128B2 (en) * | 2014-09-17 | 2019-06-25 | Ansun Biopharma, Inc. | Treatment of infection by human enterovirus D68 |
US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
WO2016115616A1 (en) * | 2015-01-21 | 2016-07-28 | Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health | Inhibition of cellular proteases as treatment for influenza |
SG10202100652VA (en) | 2015-07-21 | 2021-03-30 | Univ Jefferson | Gene therapies for neurodegenerative disorders targeting ganglioside biosynthetic pathways |
EP4218802A3 (en) | 2016-07-01 | 2023-09-27 | The Board of Trustees of the Leland Stanford Junior University | Conjugates for targeted cell surface editing |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
MX2020007024A (es) | 2018-01-03 | 2020-10-28 | Palleon Pharmaceuticals Inc | Sialidasas humanas recombinantes, proteinas de fusion de sialidasa y metodos para usar las mismas. |
GB201800274D0 (en) * | 2018-01-08 | 2018-02-21 | Enzymatica Ab | Novel treatments |
GB201803197D0 (en) | 2018-02-27 | 2018-04-11 | Pneumagen Ltd | Viral treatment |
CA3106983A1 (en) * | 2018-07-20 | 2020-01-23 | Ansun Biopharma, Inc. | Delivery of sialidase to cancer cells, immune cells and the tumor microenvironment |
CN109991649B (zh) * | 2019-03-26 | 2021-04-06 | 华中科技大学 | 一种制备无机闪烁体膜的方法 |
JP7343890B2 (ja) * | 2019-04-26 | 2023-09-13 | 国立大学法人東海国立大学機構 | シアリダーゼ活性を有する酵素剤及びその利用 |
CN110038122A (zh) * | 2019-05-23 | 2019-07-23 | 武汉真福医药股份有限公司 | 枯草杆菌纤溶酶在治疗支气管炎药物中的应用 |
CN114340637A (zh) | 2019-07-03 | 2022-04-12 | 阿伊里斯株式会社 | 用于治疗流感病毒感染症的药物组合物 |
WO2021217053A1 (en) * | 2020-04-24 | 2021-10-28 | Rezolute, Inc. | Plasma kallikrein inhibitors for the treatment of ards and related conditions |
US20230218794A1 (en) * | 2020-06-10 | 2023-07-13 | The Penn State Research Foundation | Process and system to lessen human coronavirus transmission and spread |
WO2022147480A1 (en) | 2020-12-30 | 2022-07-07 | Ansun Biopharma, Inc. | Oncolytic virus encoding sialidase and multispecific immune cell engager |
AU2022289484A1 (en) * | 2021-06-09 | 2023-12-07 | Microbial Machines, Inc. | Engineered microorganisms for detection of diseased cells |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3439089A (en) * | 1968-03-27 | 1969-04-15 | Merck & Co Inc | Medicated hard candy |
US5643758A (en) * | 1987-03-10 | 1997-07-01 | New England Biolabs, Inc. | Production and purification of a protein fused to a binding protein |
EP0286239B1 (en) * | 1987-03-10 | 1996-03-13 | New England Biolabs, Inc. | Production and purification of a protein fused to a binding protein |
RU2054180C1 (ru) | 1991-08-21 | 1996-02-10 | Жирнов Олег Петрович (н/п) | Способ лечения вирусных респираторных инфекций |
US5376633A (en) * | 1992-09-30 | 1994-12-27 | Lezdey; John | Method for deactivating viruses in blood component containers |
US5985859A (en) * | 1994-04-14 | 1999-11-16 | The University Of Alabama | Methods of inhibiting bacterial sialidase |
US6083733A (en) * | 1994-06-14 | 2000-07-04 | Gist-Brocades B.V. | Thermostable xylanases |
CN100409844C (zh) * | 1995-02-27 | 2008-08-13 | 吉里德科学公司 | 神经氨酸苷酶抑制剂 |
GB9513683D0 (en) * | 1995-07-05 | 1995-09-06 | Ciba Geigy Ag | Products |
WO1998031817A2 (en) | 1997-01-14 | 1998-07-23 | Hopital Sainte-Justine | Human lysosomal sialidase and therapeutic uses thereof |
US6251392B1 (en) * | 1997-10-20 | 2001-06-26 | Epicyte Pharmaceuticals, Inc. | Epithelial cell targeting agent |
US6737511B1 (en) * | 1999-08-16 | 2004-05-18 | The United States Of America As Represented By The Department Of Health And Human Services | Receptor-mediated uptake of an extracellular BCL-xL fusion protein inhibits apoptosis |
US20020025320A1 (en) * | 1999-08-20 | 2002-02-28 | Prosper Boyaka | Sialidases as mucosal adjuvants |
CN1405562A (zh) * | 2002-10-24 | 2003-03-26 | 肖洪武 | 一种唾液酸酶测定试剂 |
US7807174B2 (en) * | 2002-11-22 | 2010-10-05 | Nexbio, Inc. | Class of therapeutic protein based molecules |
WO2004047735A2 (en) | 2002-11-22 | 2004-06-10 | Mang Yu | Broad spectrum anti-viral therapeutics and prophylaxis |
DE10258400A1 (de) * | 2002-12-13 | 2004-06-24 | N.V. Nutricia | Trans-Sialidasen aus Trypanosoma congolense |
EP1981483A1 (en) * | 2006-01-24 | 2008-10-22 | Nexbio, Inc. | Technology for preparation of macromolecular microspheres |
-
2004
- 2004-09-10 US US10/939,262 patent/US7807174B2/en active Active
-
2005
- 2005-07-21 DK DK15180371.5T patent/DK3018204T3/en active
- 2005-07-21 CN CN2005800372268A patent/CN101426906B/zh active Active
- 2005-07-21 PT PT151803715T patent/PT3018204T/pt unknown
- 2005-07-21 TR TR2019/05393T patent/TR201905393T4/tr unknown
- 2005-07-21 EP EP19153015.3A patent/EP3530734A1/en not_active Withdrawn
- 2005-07-21 BR BRPI0515646A patent/BRPI0515646B8/pt active IP Right Grant
- 2005-07-21 DK DK05790917.8T patent/DK1786902T3/en active
- 2005-07-21 ES ES05790917.8T patent/ES2554787T3/es active Active
- 2005-07-21 PT PT57909178T patent/PT1786902E/pt unknown
- 2005-07-21 JP JP2007531167A patent/JP4764881B2/ja active Active
- 2005-07-21 CA CA2823429A patent/CA2823429C/en active Active
- 2005-07-21 EP EP17164276.2A patent/EP3241898B1/en active Active
- 2005-07-21 CA CA2578050A patent/CA2578050C/en active Active
- 2005-07-21 RU RU2007112502/10A patent/RU2468080C2/ru active
- 2005-07-21 EP EP15180371.5A patent/EP3018204B1/en active Active
- 2005-07-21 ES ES15180371.5T patent/ES2626845T3/es active Active
- 2005-07-21 CN CN201310239638.6A patent/CN104017787B/zh active Active
- 2005-07-21 PT PT17164276T patent/PT3241898T/pt unknown
- 2005-07-21 WO PCT/US2005/025831 patent/WO2006031291A2/en active Application Filing
- 2005-07-21 KR KR1020077008112A patent/KR20070064619A/ko not_active Application Discontinuation
- 2005-07-21 ES ES17164276T patent/ES2721172T3/es active Active
- 2005-07-21 EP EP05790917.8A patent/EP1786902B1/en active Active
- 2005-07-21 AU AU2005285461A patent/AU2005285461B2/en active Active
- 2005-07-21 DK DK17164276.2T patent/DK3241898T3/en active
-
2007
- 2007-03-07 IL IL181779A patent/IL181779A/en active IP Right Grant
- 2007-04-10 ZA ZA200702915A patent/ZA200702915B/xx unknown
-
2008
- 2008-10-22 US US12/256,230 patent/US7645448B2/en active Active
-
2010
- 2010-07-05 JP JP2010153231A patent/JP5307082B2/ja not_active Expired - Fee Related
- 2010-09-02 IL IL207957A patent/IL207957A/en active IP Right Grant
-
2015
- 2015-03-03 HK HK15102164.9A patent/HK1201562A1/zh unknown
- 2015-09-06 IL IL241227A patent/IL241227B/en active IP Right Grant
-
2016
- 2016-10-28 HK HK16112471.5A patent/HK1224329A1/zh unknown
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111183220A (zh) * | 2017-05-26 | 2020-05-19 | 杰诺维斯公司 | 用于聚糖分析的工具 |
CN111183220B (zh) * | 2017-05-26 | 2024-03-22 | 杰诺维斯公司 | 用于聚糖分析的工具 |
CN111065733A (zh) * | 2017-09-05 | 2020-04-24 | 角斗士生物科学公司 | 靶向外泌体的方法 |
US11981723B2 (en) | 2017-09-05 | 2024-05-14 | GLAdiator Biosciences, Inc. | Method of targeting exosomes |
CN111450236A (zh) * | 2020-02-25 | 2020-07-28 | 西北大学 | 一种用于阻断冠状病毒感染的制剂 |
CN111450236B (zh) * | 2020-02-25 | 2023-04-07 | 西北大学 | 一种用于阻断冠状病毒感染的制剂 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101426906B (zh) | 一类新颖的以蛋白质为基础的治疗用分子 | |
US10525109B2 (en) | Class of therapeutic protein based molecules | |
CN1729013B (zh) | 广谱抗病毒化合物、药物制剂及其用途 | |
AU2008200954A1 (en) | Broad spectrum anti-viral therapeutics and prophylaxis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1128935 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1128935 Country of ref document: HK |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20170216 Address after: American California Patentee after: Ansun Biopharmaceutical Inc. Address before: American California Patentee before: Fang Fang Patentee before: Malakhov Michael |